Related Experiment Video
Updated: Jul 18, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
Long-term prognosis of hypertrophic cardiomyopathy after surgery
Sandhya K Balaram1, Daniel G Swistel
1Division of Cardiovascular and Thoracic Surgery, St. Luke's/Roosevelt Hospital Center, New York, NY, USA. dswistel@chpnet.org.
Insights
Septal myectomy significantly improves symptoms and reduces left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients. This surgical therapy has demonstrated consistent benefits with decreased morbidity and mortality over 40 years.
Area of Science:
- Cardiovascular Surgery
- Cardiology
- Medical Treatment Outcomes
Background:
- Hypertrophic cardiomyopathy (HCM) is a complex condition with varied treatment strategies.
- Symptomatic patients with significant left ventricular outflow tract (LVOT) obstruction often require intervention.
- Septal myectomy is a primary surgical option for managing obstructive HCM.
Purpose of the Study:
- To review the historical and current outcomes of surgical septal myectomy for hypertrophic cardiomyopathy.
- To evaluate symptom improvement, morbidity, mortality, and long-term survival post-procedure.
- To assess the safety and efficacy of septal myectomy in specialized centers.
Main Methods:
- Literature review focusing on early and recent studies of septal myectomy outcomes.
- Analysis of data from specialized centers with high patient volumes for septal myectomy.
- Assessment of symptom relief, LVOT gradient reduction, and survival rates.
Main Results:
- Surgical therapy for HCM has shown consistent symptom improvement and LVOT gradient reduction over four decades.
- Significant decreases in morbidity and mortality associated with septal myectomy have been observed.
- Improvements are attributed to advancements in cardiac surgery techniques and understanding of HCM pathophysiology.
Conclusions:
- Septal myectomy is a safe, reproducible, and effective procedure for symptomatic patients with obstructive HCM.
- The procedure leads to substantial improvements in patient symptoms and long-term survival.
- Continued advancements in surgical techniques enhance the positive outcomes of septal myectomy.
Abstract:
Hypertrophic cardiomyopathy is a heterogeneous disease with both medical and surgical treatment options. Patients who are symptomatic with a left ventricular outflow tract (LVOT) gradient of >50 mm Hg are referred for septal myectomy. A review of both early and recent literature of outcomes of surgical therapy was performed. Specialized centers referred large numbers of patients for septal myectomy were the focus. Overall improvement in symptoms, morbidity, mortality, and long-term survival were reviewed. Over the past 40 years, surgical therapy has shown consistent improvement in symptoms and reduction of LVOT gradient for patients with hypertrophic cardiomyopathy. Furthermore, there has been a significant decrease in both morbidity and mortality for septal myectomy with improved techniques in the field of cardiac surgery and better understanding of the pathophysiology of the disease process. Surgical resection of the septum for hypertrophic cardiomyopathy is a safe, reproducible, and effective procedure for symptomatic patients with a significant LVOT obstruction.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy VI: Nursing Management
